Findings from a new study by Duke researchers are shifting the way one of the deadliest forms of lung cancer is understood and offering fresh insights that could revolutionize treatment approaches.

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells ...

Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $46 and keeps an Overweight rating on the shares ...

A doctor at an Overland Park hospital made history performing the area's first non-invasive liver tumor treatment.

Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical ...

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that the company’s abstract featuring first clinical data from ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

Small cell lung cancer cells that metastasize to the brain cozy up to neurons and form working electrical connections, called ...

Welcome to our first fireside chat of the morning. I'm Robert Burns, the Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined today by Chris Senner, the CFO of Exelixis; as ...